Replies to post #18013 on Cel Sci Corporation (CVM)

[alexander77]

These are all very valuable explanations for pages 5-6-7 of the 2016 annual report. AF posted an understandable concern, but I think the answer to the concern is not the science but the former CRO.
The best proof Multikine has a decent chance of succeess is the fact the tumor size could be elminated or reduced in 50% of the patients.
Good news also is the 298th hasn't occured.
I remain my market cap target of at least $2b if phase 3 results are positive.
If you see MBOT raised from $1/share to $20/share on positive preclinical results, CVM could do that too.